Safety of granulocyte colony-stimulating factor in normal donors.
Granulocyte colony-stimulating factor (G-CSF), which is widely used to mobilize peripheral blood stem cells (PBSC) from normal donors, has led to the use of PBSC as a major alternative to bone marrow for patients undergoing allogeneic transplants. Safety issues related to the administration of G-CSF to normal donors, however, are still under study. The short-term effects after G-CSF administration are well known and manageable. G-CSF induces a hypercoagulable state, which may predispose certain donors to thrombotic complications. A dose of 10 microg/kg/d for 5 days has been recommended for routine clinical use, but the optimal dose and schedule for PBSC collection are still being defined. Small studies to date have shown no late effects of G-CSF administration but there is insufficient information regarding any long-term adverse effects or risks. Although the administration of G-CSF to normal donors for PBSC collection appears safe, longer follow-up is required.
Gutierrez-Delgado
F
F
Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington 98109, USA.
Bensinger
W
W
D001782:Blood Donors; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000633:toxicity*; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans
D016179:Granulocyte Colony-Stimulating Factor